Ain Holdings Inc. · TSE:9627
Ain — Q3 FY4/26 Earnings Presentation
19 slides from Ain's earnings presentation, Mar 17, 2026
Slide 1: FY4/26 3Q IR Presentation
FY4/26 3Q IR PRESENTATION March 17, 2026
Slide 2: Results Overview
Results Overview © AIN HOLDINGS INC. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L Net sales increased 41.0% YoY and 0.2% against the plan due to the consolidation of Sakura Pharmacy Group. Ordinary profit increased 48.0% YoY and 11.6% against the plan. FY4/25 3Q FY4/26 3Q FY4/26 3Q YoY YoY Vs plan （¥ million） results plan results change change(%) (%) Net sales 33
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business (Consolidated) Net sales increased 42.0% YoY and 0.8% against the plan because the average prescription price rose due to an increase in high-cost prescriptions, as well as the consolidation of Sakura Pharmacy Group, etc. Segment profit increased 38.6% YoY and 11.8% agai
Slide 5: Retail Business (Consolidated)
Retail Business (Consolidated) Although Francfranc, which joined the group in the previous fiscal year, contributed fully, net sales up 42.2% YoY and decreased 3.3% against the plan. This was due to the failure to meet the planned targets for the number of customers and average spending per customer
Slide 6: Consolidated B/S
Consolidated B/S Net cash became ¥ (130.5) billion due to funds procured for the acquisition of shares associated with the consolidation of Sakura Pharmacy Group through borrowings. End-FY4/25 End-FY4/26 3Q (¥ million) (¥ million) Assets Liabilities and Net Assets Assets Liabilities and Net Assets C
Slide 7: Assets
Assets The balance of total assets increased ¥213.0 billion from the end of fiscal year 2025, mainly reflecting increases in goodwill due to the acquisition of shares associated with the consolidation of Sakura Pharmacy Group. (¥ million) End-FY4/25 3Q End-FY4/25 End-FY4/26 3Q Change Cash and deposi
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets Accounts payable – trade increased ¥ 42.7 billion due to the consolidation of Sakura Pharmacy Group. Short-term and long-term borrowings increased ¥ 148.6 billion due to funds procured for the acquisition of shares associated with the consolidation. (¥ million) End-FY4/25
Slide 9: Review
Review © AIN HOLDINGS INC. All Rights Reserved. 8
Slide 10: Consolidated (YoY results)
Consolidated (YoY results) Operating profit increased ¥8.7 billion and ordinary profit increased ¥6.5 billion YoY due to the consolidation of Francfranc in the previous fiscal year, and Sakura Pharmacy Group in the current fiscal year. Net sales Operating profit Ordinary profit ¥336.8 billion ¥474.8
Slide 11: Consolidated (vs plan)
Consolidated (vs plan) Operating profit increased ¥1.9 billion and ordinary profit increased ¥2.1 billion against the plan because the number of prescriptions at existing stores and stores opened in the previous year remained steady, and the average prescription price rose due to an increase in high
Slide 12: Number of Pharmacies and Stores
Number of Pharmacies and Stores ■ Plan and Results FY4/26 3Q FY4/26 Plan Results Plan Prospect Dispensing pharmacy 886 887 901 902 Organic 28 32 35 41 M&A 858 855 866 861 Opening Retail 14 16 26 21 AINZ & TULPE 11 11 20 14 Francfranc 3 5 6 7 Total 900 903 927 923 Dispensing Pharmacy 20 37 Closure 30
Slide 13: Transition of main dispensing fee revision
Transition of main dispensing fee revision Revision in 2022 Revision in 2024 Revision in 2026 (Revision) (Revision) (Revision) 1 42pts 1 45pts 1 47pts 2 26pts 2 29pts 2 30pts Over 4,000 times and over 70% Over 4,000 times and over 70%(Top3 medical institutions) Over 4,000 times and over 70%(Top3 med
Slide 14: Impact Transition of Dispensing Fee Revisions
Impact Transition of Dispensing Fee Revisions The company has been affected by the revision of dispensing fees and changes in social conditions. While fulfilling the roles required of pharmacies, we will pursue business expansion including M&A in both business and strengthen our management base, the
Slide 15: FY4/26 Plan (Dispensing Pharmacy Business)
FY4/26 Plan (Dispensing Pharmacy Business) The group forecasts net sales increase 43.3% YoY and segment profit increase 33.0% YoY due to the consolidation of Sakura Pharmacy Group. FY4/24 FY4/25 FY4/26 YoY YoY （¥ million） results results plan change change(%) Net sales 357,571 384,783 551,500 +166,7
Slide 16: FY4/26 Plan (Retail Business)
FY4/26 Plan (Retail Business) The group forecasts net sales increase 36.1% YoY and segment profit increase 56.1% YoY due to the sales of AINZ & TULPE remained firm, in addition to the Francfranc contribution to the full year. FY4/24 FY4/25 FY4/26 YoY YoY （¥ million） results results plan change chang
Slide 17: FY4/26 Plan (Consolidated)
FY4/26 Plan (Consolidated) The group forecasts net sales for the fiscal year ending April 30, 2026 increase 41.4% YoY and ordinary profit increase 46.6% YoY, due to the revision of the dispensing pharmacy business plan results from the consolidation of Sakura Pharmacy Group. FY4/24 FY4/25 FY4/26 YoY
Slide 18: AIN HOLDINGS INC. Corporate Planning Division
Inquiries related to this presentation should be addressed to AIN HOLDINGS INC. Corporate Planning Division TEL: +81-3-5333-1812 https://www.ainj.co.jp/corporate/ This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been
Slide 19: AIN GROUP
AIN GROUP